Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
NCT07370506Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Countries
- 1
- Sponsor
- Tanta University
- Modality
- Small Molecules
- Drugs
- telmisartan
- Conditions
- doxorubicin-induced cardiomyopathy
01
Overview
Phase 2 trial of telmisartan in doxorubicin-induced cardiomyopathy (2 arms), sponsored by Tanta University. Primary endpoint: Change in Left Ventricular Ejection Fraction. Planned start Feb 2026; status: not yet recruiting.
02
Design
2 armsTelmisartan Group
Participants receiving telmisartan in addition to standard doxorubicin-based chemotherapy.
Control Group
Participants receiving standard doxorubicin-based chemotherapy without telmisartan.
03
Who it enrols
Female breast cancer patients aged 18-65, newly diagnosed and chemotherapy-naïve, with baseline LVEF >= 55%, excluding those with cardiovascular, liver, or renal disease, high blood pressure, or prior ARB/ACE inhibitor use.
04
Endpoints
Primary
Change in Left Ventricular Ejection Fraction
Secondary
Change in High-Sensitivity Cardiac Troponin T Levels
Change in N-terminal pro-B-type Natriuretic Peptide Levels
Beyond the preview
Go deeper on NCT07370506.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370506.